The VP1-unique region of parvovirus B19 induces myocardial injury in mice

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 2, 2010, Pages 121-128

  Nie, Xiaojing ^a   Zhang, Guocheng ^a   Xu, Dongliang ^a   Sun, Xin ^a   Li, Zhihong ^a   Li, Xiaoqing ^a   Zhang, Xuehong ^a   He, Fei ^b   Li, Yunming ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBUTYRATE DEHYDROGENASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATINE KINASE ISOENZYME; LACTATE DEHYDROGENASE; PROTEIN VP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; FERMENTATION; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE INJURY; HOST; MALE; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARVOVIRUS; PATHOGENESIS; PROTEIN EXPRESSION; ZYMOGRAPHY;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; ENZYMES; ESCHERICHIA COLI; FEMALE; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; PARVOVIRUS B19, HUMAN; RECOMBINANT PROTEINS; VIRULENCE FACTORS;

EID: 75749148323     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365540903321580     Document Type: Article

References (27)

1. Escher F, Modrow S, Sabi T, Kühl U, Lassner D, Schultheiss HP, et al. Parvovirus B19 profi les in patients presenting with acute myocarditis and chronic dilated cardiomyopathy. Med Sci Monit 2008;14:CR589-97
2. Lindner J, Noutsias M, Lassner D, Wenzel J, Schultheiss HP, Kuehl U, et al. Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J Clin Virol 2009;44:27-32
3. Savarese I, De Carolis MP, Costa S, De Rosa G, De Carolis S, Lacerenza S, et al. Atypical manifestations of congenital parvovirus B19 infection. Eur J Pediatr 2008;167:1463-1466
4. Dennert R, Schalla S, Suylen RJ, Eurlings L, Heymans S. Giant cell myocarditis triggered by a parvovirus B19 infection. Int J Cardiol 2009;134:115-116
5. Maisch B, Ristic AD, Portig I, Pankuweit S. Human viral cardiomyopathy. Front Biosci 2003;8:39-67
6. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581-1590
7. Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965-1970
8. Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol 2002;76:2014-2018
9. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975;1:72-73
10. Lu J, Zhi N, Wong S, Brown KE. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J Infect Dis 2006;193:582-590
11. Zádori Z, Szelei J, Lacoste MC, Li Y, Gariépy S, Raymond P, et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001;1:291-302
12. Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, et al. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 2008; 374:444-452
13. Rosenfeld SJ, Yoshimoto K, Kajigaya S, Anderson S, Young NS, Field A, et al. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest 1992;89:2023-2029
14. Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, Young NS, et al. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 1999;73:1974-1979
15. Corcoran A, Doyle S, Waldron D, Nicholson A, Mahon BP. Impaired gamma interferon responses against parvovirus B19 by recently infected children. J Virol 2000;74:9903-9910
16. Ros C, Gerber M, Kempf C. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol 2006;80: 12017-12024
17. Escher F, Kuhl U, Sabi T, Suckau L, Lassner D, Poller W, et al. Immunohistological detection of parvovirus B19 capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients. Med Sci Monit 2008;14: CR333-8
18. Seishima M, Shibuya Y, Suzuki S, Arakawa C. Acute heart failure associated with human parvovirus B19 infection. Clin Exp Dermatol 2008;33:588-590
19. Donal E, Piriou N, Nanadoumgar H, Mignot A, Bressolette C, Toquet C, et al. Viral cardiomyopathy. Arch Mal Coeur Vaiss 2005;98:984-991
20. Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R. Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 2004;193:101-107
21. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586-597
22. Hood D, Van Lente F, Estes M. Serum enzyme alterations in chronic muscle disease. A biopsy-based diagnostic assessment. Am J Clin Pathol 1991;95:402-407
23. Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am 1994;20:845-856
24. Wu AH. Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. Ann Clin Lab Sci 1999; 29:18-23
25. Takagi Y, Yasuhara T, Gomi K. Creatine kinase and its isozymes. Rinsho Byori 2001;(Suppl 116):52-61
26. Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, Hsu TC. The association of VP1 unique region protein in acute parvovirus B19 infection and antiphospholipid antibody production. Clin Chim Acta 2007;378:59-65
27. Tzang BS, Tsai CC, Chiu CC, Shi JY, Hsu TC. Up-regulation of adhesion molecule expression and induction of TNF-α on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta 2008; 395:77-83